FENC logo

FENNEC PHARMACEUTICALS INC

FENCNASDAQ
🏆 #3186 by market capEarnings Nov 11US Equity
$167.56▼ $11.91 (−7.11%)
Simulated price
🔔
Track FENC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 7.1%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$380M
Small Cap
📈Revenue Growth (YoY)
-6.1%
Declining
📊Gross Margin
93.7%
High
💵FCF Margin
-3.4%
Thin
⚖️P/S Ratio
6.4x
Fair
Otter Score
64
Fair
No chart data available for FENC.

Trading Snapshot

Day Range
$165.56 – $170.64
52-Week Range
$5.65 – $13.25
Volume
$3.59B
Avg Volume
$4.76B
Shares Outstanding
34.7M
Next Earnings
Nov 2, 2026

Fundamentals Snapshot

Annual Revenue
$45M
Last Q Revenue
$18M
P/E Ratio
-84.2
P/S Ratio
6.4x
EPS (TTM)
$-0.09
Dividend Yield
0.00%
Dilution (1yr)
+13.5%

Why Investors Own FENC

  • ✓High-growth profile — revenue up +25.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 34% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

FENC logo

FENNEC PHARMACEUTICALS INC

FENC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$45M▼ −6.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.6%▼ −1.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −356.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$12M▼ −146.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.2M▲ +13.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$37M▲ +$29M YoY
StockOtter · stockotter.space

About FENNEC PHARMACEUTICALS INC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy3
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
MarketWatch·2h ago

FENNEC PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift FENC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

FENNEC PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.